Sana Biotechnology Inc. entered into a strategic collaboration with Mayo Clinic to advance its SC451 type 1 diabetes program, a partnership that will focus on clinical development, regulatory strategy, and potential commercialization pathways for the therapy.
Under the terms of the collaboration, Sana sold 7,507,507 shares to Mayo Clinic at $3.33 per share, generating approximately $25 million in equity capital. Mayo Clinic also secured an option to purchase an additional 7,507,507 shares at the same price by August 31, 2026. The proceeds will be used to support product development under the collaboration and license agreement, including the SC451 program.
The partnership provides scientific validation from a leading medical institution and is expected to accelerate the clinical development of SC451. Sana plans to file an Investigational New Drug application and initiate a Phase 1 trial for SC451 in 2026, positioning the therapy for potential regulatory approval and commercialization.
Financially, the equity infusion extends Sana’s cash runway into 2027. The company reported $138.4 million in cash as of December 31, 2025, and the $24.9 million net proceeds from the sale are expected to cover operating expenses and support ongoing clinical activities, addressing prior concerns about cash burn and going‑concern status.
Management emphasized the significance of the collaboration: CEO Steve Harr said the company aims to start a clinical trial for SC451 this year, while Mayo Clinic’s research dean Vijay Shah highlighted the combined expertise in cell therapy and transplant immunology that will help evaluate the investigational approach for patients with type 1 diabetes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.